Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 20.25%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with significant regulatory progress and promising clinical data on TSHA-102 for Rett syndrome. The company is financially stable with a reduced net loss and decreased R&D expenses, although there was an increase in general and administrative costs.Company Guidance
During the Taysha Gene Therapies First Quarter 2025 earnings call, the company provided significant updates on their TSHA-102 gene therapy program for Rett syndrome. The company announced the completion of dosing for 10 patients in Part A of their REVEAL Phase 1/2 trials, with six patients receiving a high dose of TSHA-102. Encouragingly, TSHA-102 was generally well-tolerated across both high and low dose cohorts with no treatment-related serious adverse events or dose-limiting toxicities as of April 10, 2025. Taysha highlighted their alignment with the FDA on key elements of their pivotal Part B trial design, which eliminates the need for a formal end-of-phase meeting, potentially expediting study initiation. Financially, the company reported a net loss of $21.5 million for Q1 2025, with $116.6 million in cash reserves expected to support operations into Q4 2026. Overall, Taysha expressed confidence in the therapeutic potential of TSHA-102 and its path towards regulatory approval.Progress in TSHA-102 Gene Therapy Program
Significant regulatory and clinical progress with TSHA-102 for Rett syndrome, including FDA alignment on pivotal trial design without the need for an end-of-phase meeting.
Positive Clinical Data
TSHA-102 has shown early clinical improvements and functional gains in pediatric, adolescent, and adult patients with Rett syndrome, which are unlikely in the untreated population.
Strong Financial Position
Taysha has $116.6 million in cash and cash equivalents, with cash resources expected to support operations into the fourth quarter of 2026.
Decreased R&D Expenses
Research and development expenses decreased by $5.1 million compared to the prior year, driven by reduced GMP batch activities.
TSHA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSHA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $2.37 | $2.56 | +8.02% |
Feb 26, 2025 | $1.70 | $1.62 | -4.71% |
Nov 13, 2024 | $2.21 | $2.27 | +2.71% |
Aug 12, 2024 | $2.09 | $2.04 | -2.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Taysha Gene Therapies (TSHA) report earnings?
Taysha Gene Therapies (TSHA) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Taysha Gene Therapies (TSHA) earnings time?
Taysha Gene Therapies (TSHA) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSHA EPS forecast?
TSHA EPS forecast for the fiscal quarter 2025 (Q2) is -0.08.